BioCryst discontinues flu compound

BCRX discontinued development of its peramivir oral neuraminidase inhibitor after the product failed to meet the primary endpoint in a 1,246-patient Phase III influenza study. The product did not improve the length of time from the first dose to the onset of clinically significant relief of influenza symptoms compared to placebo, the primary endpoint (p=0.17). ...